Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) originate from
neuroendocrine cells in the gastrointestinal tract. They are heterogeneous, and though …

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms that
require a multidisciplinary approach for an optimal management. The lack of effectiveness of …

Background: The characteristic clinical heterogeneity and mostly slow-growing behavior of
gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) cause problems in finding …

Gastroenteropancreatic neuroendocrine neoplasms are heterogeneous in their clinical
behavior and require therapies specially tailored according to staging, grading, origin and …

Pancreatic endocrine tumors (PETs) are rare neoplasms which account for 1% to 2% of all
pancreatic malignancies. The diagnostic, grading and prognostic criteria for PETs have …

The molecular events leading to gastroenteropancreatic neuroendocrine tumor (GEP-NET)
formation are largely unknown. Over the past decades, systemic chemotherapies have been …

Opinion statement Neuroendocrine tumors (NETs) are a heterogeneous group of
malignancies characterized by variable but most often indolent biologic behavior. Well …

Clinical trials indicate efficacy of drugs inhibiting the mammalian target of rapamycin (mTOR)
in the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NET); however …

The serine/threonine kinase mammalian target of rapamycin (mTOR) plays a central role in
regulating critical cellular processes such as growth, proliferation, and protein synthesis. The …

Medical therapy of pancreatic neuroendocrine tumors (P-NET) may take advantage of
Everolimus treatment. However, the extent of therapeutic response cannot be predicted. This …